The Latest Cardiac and Vascular News
Acquisition is part of Bayer’s innovation strategy in radiology Blackford Analysis provides cutting-edge radiology AI platform technology Following closing of the acquisition, Blackford Analysis to become part of Bayer’s well established “arm’s length” operating model to preserve the company’s entrepreneurial culture January 18, 2023 02:30 AM Eastern Standard Time PITTSBURGH–(BUSINESS WIRE)–Bayer today announced the acquisition […]
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in the prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack1,2 OCEANIC-AF and OCEANIC-STROKE are expected to enroll up to 30,000 patients in over […]
Further analysis from FIDELITY, a prespecified pooled analysis of FIDELIO-DKD and FIGARO-DKD, explores the effect of KERENDIA® (finerenone) on cardiovascular (CV) and kidney outcomes in patients with chronic kidney disease associated with type 2 diabetes, with and without history of CV disease First Phase IIb PACIFIC trial, PACIFIC-AF, gathered information about the proper dosing of asundexian […]
WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its investigational drug asundexian (BAY2433334) as a potential treatment for secondary prevention in patients with a non-cardioembolic ischemic stroke. Asundexian is an oral inhibitor of Factor Eleven (FXIa) 1 that Bayer is developing as a potential treatment for […]
Market availability of the cardiovascular disease prevention module co-developed with Bayer demonstrates One Drop’s continued expansion into new therapeutic areas NEW YORK, Oct. 27, 2021 /PRNewswire/ — One Drop, a leader in precision health solutions for people living with chronic conditions worldwide, today announced the release of a digital, AI-enabled cardiovascular disease (CVD) prevention module. The new […]
Seven U.S. researchers working to advance pulmonary hypertension (PH) science and patient care awarded a combined one million dollars in grants Application for the 2021 PHAB Awards is now live for eligible researchers to submit their proposals WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer announced the 2020 recipients of the annual Pulmonary Hypertension Accelerated Bayer (PHAB) Awards, a U.S.-based […]
FIGARO-DKD is the first contemporary cardiorenal outcomes trial with the majority of patients who had an eGFR ≥60 ml/min/1.73m2 to show cardiovascular benefit in chronic kidney disease associated with type 2 diabetes; patients were included in this study if they had UACR levels 30–5000 mg/g1 Additionally, results from FIDELITY, a prespecified meta-analysis of Phase III trials […]
The prospective, randomized, controlled, open-label study, which included outcomes from 226 patients with pulmonary arterial hypertension (PAH) (WHO Group 1), met its primary endpoint WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer today announced that The Lancet Respiratory Medicine has published results from the Phase IV REPLACE (Riociguat rEplacing PDE-5i therapy evaLuated Against Continued PDE-5i thErapy) study in which intermediate-risk adult patients with pulmonary arterial hypertension […]
Bayer and Blackford Analysis have entered into a development and license agreement to establish an artificial intelligence (AI) platform for medical imaging. This agreement supports Bayer’s commitment to expanding its AI capabilities and accelerating innovation in radiology INDIANOLA, Pa.–(BUSINESS WIRE)–During the week of November 29 to December 5, leaders in imaging gather at the Radiological […]
Late-breaking data presented at AHA 2020 Scientific Sessions and published simultaneously in Circulation WHIPPANY, N.J.–(BUSINESS WIRE)–Bayer announced today late-breaking data from a pre-specified exploratory subgroup analysis of the FIDELIO-DKD Phase III study, in which the investigational drug finerenone, compared to placebo, reduced the risk of cardiovascular (CV) outcomes in patients with chronic kidney disease (CKD) and […]
